Theravance Biopharma

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

Theravance Bio (TBPH) Up 10.1% Since Last Earnings Report: Can It Continue?

Theravance's (TBPH) loss narrows in the fourth quarter of 2020 while revenues meet the consensus estimate.

Theravance (TBPH) Q4 Earnings Top Estimates, Revenues In Line

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q4 2020 Results - Earnings Call Transcript

Shares of Theravance Biopharma (NASDAQ:TBPH) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 21.37% over the past year to ($0.92), which beat the estimate of ($1.02).

Theravance Biopharma: Q4 Earnings Insights

DUBLIN, Feb. 10, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in investor events as follows: Management will be...

Theravance Biopharma to Participate in Upcoming Investor Conferences

DUBLIN, Feb. 9, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its fourth quarter and full year 2020 financial results...

Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021

DUBLIN, Jan. 5, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, will webcast its presentation at the 39th Annual J.P. Morgan...

Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference

Theravance Bio (TBPH) Down 12.5% Since Last Earnings Report: Can It Rebound?

Today, we revisit Theravance Biopharma for the first time in over a year. The stock has had a challenging year in 2020, but there are some potentially significant catalysts on the horizon in 2021.

Theravance Biopharma Is A Buy

Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.

Theravance (TBPH) Drops on Q3 Earnings Miss, Revenues In Line

Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2020 Results - Earnings Call Transcript

Theravance Bio (TBPH) delivered earnings and revenue surprises of -18.37% and 3.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates

DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ending September 30, 2020. Theravance Biopharma's Total Revenue for the third quarter 2020 was $18.3 million....

Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its third quarter 2020 financial results and provide a...

Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020

Why Is Theravance Bio (TBPH) Down 17.7% Since Last Earnings Report?

Innoviva

Jazz Pharmaceuticals

10X Genomics

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Why This Top Venture Capitalist Is Raising Money With a Biotech SPAC

Theravance Biopharma's (TBPH) CEO Rick Winningham on Q2 2020 Results - Earnings Call Transcript

Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.

Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2

DUBLIN, Aug. 6, 2020 /PRNewswire/ -- Theravance Biopharma, Inc.

Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update

DUBLIN, July 27, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2020 financial results and provide a.

Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020

DUBLIN, July 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the...

Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D.

Theravance (TBPH) initiates dosing in a mid-stage study, evaluating its JAK inhibitor TD-0903 for the potential treatment of hospitalized patients with acute lung injury due to COVID-19.

Theravance Doses First Patient in Phase II Coronavirus Study

DUBLIN and SOUTH SAN FRANCISCO, Calif., June 25, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective...

Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound?

Theravance (TBPH) reports wider- than-expected loss in the first quarter of 2020 while sales beat estimates. The company reiterates 2020 outlook.

News for Theravance Biopharma Stock (TBPH)